Vimta Labs Board Approves 1:1 Bonus Share Issue and Final Dividend

Vimta Labs Limited has announced a 1:1 bonus share issue for its shareholders, a decision that reflects the company’s solid financial footing and commitment to rewarding investor trust. The move follows a strong performance in FY25, signalling continued confidence in future growth.

Board Recommends Bonus Issue

The Board of Directors has proposed the issue of bonus shares in the ratio of 1:1, meaning shareholders will receive one additional equity share for every share currently held. This recommendation is subject to approval at the upcoming Annual General Meeting (AGM). The decision is aimed at increasing the liquidity of the company’s shares and broadening the shareholder base.

This announcement comes alongside the declaration of a final dividend of ₹2 per equity share, reinforcing Vimta’s focus on delivering consistent returns to its investors. Bonus shares, while not offering direct monetary gains, enhance shareholder value by increasing the number of outstanding shares without diluting ownership.

Vimta Labs Q4 FY25 Results 

Vimta Labs Limited reported its financial results for the fourth quarter and financial year ended March 31, 2025, with growth in its pharmaceutical services business. The company’s total income for Q4FY25 stood at ₹960.8 million, up 31.4% year-on-year. 

EBITDA for the quarter was ₹346.8 million, with margins at 36.1%. Profit after tax (PAT) from continuing operations rose 31.2% year-on-year to ₹183.2 million, maintaining a PAT margin of 19.1%. Basic earnings per share (EPS) for Q4FY25 were ₹8.2, compared to ₹6.3 a year ago.

Read More: When Did BSE Issue Bonus Shares for the First Time?

Recent Developments

Vimta is broadening its services to include research and development for biological drugs like new therapeutic entities, biosimilars, and peptide treatments. This new biologics R&D division is slated to be fully up and running by the third quarter of the 2026 fiscal year, with revenue generation anticipated to begin in fiscal year 2027.

In other news, Vimta successfully passed a cGMP inspection by the European Medicines Agency (EMA) and a GCP audit by Kazakhstan’s Ministry of Health. Their food division also received the ‘Outstanding Laboratory Performance Award 2024’ from CII for the second year in a row.

Furthermore, Vimta has finalised its merger with EMTAC Laboratories, which will enhance the company’s range of services.

Vimta Labs Share Performance 

As of April 29, 2025, at 9:20 AM, Vimta Labs share price is trading at ₹1,061.30 per share, reflecting a surge of 3.45% from the previous closing price. Over the past month, the stock has surged by 5.93%. The stock’s 52-week high stands at ₹1,178 per share, while its low is ₹420.00 per share

Conclusion

The proposed 1:1 bonus issue by Vimta Labs underscores its commitment to shareholder value creation. The stock surged during the opening session after reporting strong earnings.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.